Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma

被引：10

作者：

Yoshida, Masahiro ^{[1
]}

Nakaya, Yosuke ^{[1
]}

Shimizu, Katsujun ^{[1
]}

Tatsumi, Naoko ^{[1
]}

Tsutsumi, Minako ^{[1
]}

Fuseya, Hoyuri ^{[1
]}

Horiuchi, Mirei ^{[1
]}

Yoshimura, Takuro ^{[1
]}

Hayashi, Yoshiki ^{[1
]}

Nakao, Takafumi ^{[1
]}

Inoue, Takeshi ^{[2
]}

Yamane, Takahisa ^{[1
]}

机构：

[1] Osaka City Gen Hosp, Dept Hematol, Osaka, Japan

[2] Osaka City Gen Hosp, Dept Pathol, Osaka, Japan

来源：

SCIENTIFIC REPORTS | 2021年 / 11卷 / 01期

关键词：

D O I：

10.1038/s41598-021-82615-4

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Treatment of patients with malignancy sometimes be delayed due to various reasons. Several studies revealed that an influence of diagnosis-to-treatment interval (DTI) on outcomes differs depending on the type of malignancy. In this study, we evaluated the influence of DTI on clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). A total of 199 patients were identified with a median DTI of 22 days. At 2 years, patients with short DTI (0-22 days) showed significantly poorer OS (62.7% vs 86.4%) and PFS (55.1% vs 75.9%) compared to those with long DTI (over 22 days). Although short DTI was strongly correlated with several known adverse factors, it remained to be an independent prognostic factor by multivariate analysis. In conclusion, our study confirmed the importance of DTI in patients with DLBCL. Researchers should consider DTI as one of the important prognostic factors and plan clinical trials to be able to enroll patients with aggressive disease requiring urgent treatment.

引用

页数：7

共 50 条

[1] Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
Masahiro Yoshida
Yosuke Nakaya
Katsujun Shimizu
Naoko Tatsumi
Minako Tsutsumi
Hoyuri Fuseya
Mirei Horiuchi
Takuro Yoshimura
Yoshiki Hayashi
Takafumi Nakao
Takeshi Inoue
Takahisa Yamane
Scientific Reports, 11
[2] Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
Maurer, Matthew J.
Ghesquieres, Herve
Link, Brian K.
Jais, Jean-Philippe
Habermann, Thomas M.
Thompson, Carrie A.
Haioun, Corinne
Allmer, Cristine
Johnston, Patrick B.
Delarue, Richard
Micallef, Ivana N.
Peyrade, Frederic
Inwards, David J.
Ketterer, Nicolas
Farooq, Umar
Fitoussi, Olivier
Macon, William R.
Molina, Thierry J.
Syrbu, Sergei
Feldman, Andrew L.
Slager, Susan L.
Weiner, George J.
Ansell, Stephen M.
Cerhan, James R.
Salles, Gilles A.
Witzig, Thomas E.
Tilly, Herve
Nowakowski, Grzegorz S.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (16) : 1603 - +
[3] Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials
Maurer, Matthew J.
Ghesquieres, Herve
Link, Brian K.
Jais, Jean-Philippe
Habermann, Thomas M.
Thompson, Carrie A.
Haioun, Corinne
Allmer, Cristine
Johnston, Patrick B.
Delarue, Richard
Micallef, Ivana N.
Peyrade, Frederic
Inwards, David J.
Ketterer, Nicolas
Farooq, Umar
Fitoussi, Olivier
Macon, William R.
Molina, Thierry Jo
Syrbu, Sergei
Feldman, Andrew L.
Slager, Susan L.
Weiner, George J.
Ansell, Stephen M.
Cerhan, James R.
Salles, Gilles Andre
Witzig, Thomas E.
Tilly, Herve
Nowakowski, Grzegorz S.
BLOOD, 2017, 130
[4] Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma
Bachy, Emmanuel
Sales, Gilles
SEMINARS IN HEMATOLOGY, 2015, 52 (02) : 107 - 118
[5] Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
Alig, Stefan
Macaulay, Charles W.
Kurtz, David M.
Duhrsen, Ulrich
Huttmann, Andreas
Schmitz, Christine
Jin, Michael C.
Sworder, Brian J.
Garofalo, Andrea
Esfahani, Mohammad Shahrokh
Nabet, Barzin Y.
Soo, Joanne
Scherer, Florian
Craig, Alexander F. M.
Casasnovas, Olivier
Westin, Jason R.
Gaidano, Gianluca
Rossi, Davide
Roschewski, Mark
Wilson, Wyndham H.
Meignan, Michel
Diehn, Maximilian
Alizadeh, Ash A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (23) : 2605 - +
[6] Hypercalcemia at diagnosis of diffuse large B-cell lymphoma is not uncommon and is associated with high-risk features and a short diagnosis-to-treatment interval
Gauchy, Anne-Cecile
Kanagaratnam, Lukshe
Quinquenel, Anne
Gaillard, Baptiste
Rodier, Cyrielle
Godet, Sophie
Delmer, Alain
Durot, Eric
HEMATOLOGICAL ONCOLOGY, 2020, 38 (03) : 326 - 333
[7] Shorter Diagnosis-to-Treatment Interval in Diffuse Large B-Cell Lymphoma is Associated With Inferior Overall Survival in a Large, Population-Based Registry
Blunt, Danielle N.
Smyth, Liam
Nagamuthu, Chenthila
Gatov, Evgenia
Croxford, Ruth
Mozessohn, Lee
Cheung, Matthew C.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (06): : 719 - 725
[8] Diagnosis and treatment of diffuse large B-cell lymphoma
Mey, Ulrich
Hitz, Felicitas
Lohri, Andreas
Pederiva, Stefanie
Taverna, Christian
Tzankov, Alexander
Meier, Oliver
Yeow, Karen
Renner, Christoph
SWISS MEDICAL WEEKLY, 2012, 142
[9] Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma
Chowdhury, Sayan Mullick
Bhatta, Subodh
Voorhees, Timothy J.
Annunzio, Kaitlin
Bond, David A.
Sawalha, Yazeed
Sigmund, Audrey
Hanel, Walter
Sehgal, Lalit
Alinari, Lapo
Baiocchi, Robert
Maddocks, Kami
Christian, Beth
Jones, Dan
Epperla, Narendranath
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
[10] Analysis of survival and prognsis in 409 newly diagnosed patients with diffuse large B-cell lymphoma
文菁菁
ChinaMedicalAbstracts(InternalMedicine), 2014, 31 (02) : 120 - 121

← 1 2 3 4 5 →